Compare Becton Dickinson and Co (BDX) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs KLA Corp. — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while KLA Corp. trades at $202.49 (market cap $251.82B). The key difference: KLA Corp. is far larger — about 5.1× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.34%). Which is the better fit depends on your goals.
| BDX | KLAC | |
|---|---|---|
Market Cap | $48.93B | $251.82B |
Sector | Health | Technology |
52-Week High | $185.39 | $301.71 |
52-Week Low | $138.62 | $84.39 |
Enterprise Value | $65.03B | $253.07B |
Dividend Yield | 2.34% | 0.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
KLA Corporation (KLAC) trades at $198.11, up 2.53% today, with a neutral technical signal despite bullish moving averages. The stock shows strong fundamentals, including a 35.57% net income margin and consistent earnings beats, with Q3 2026 EPS expected at $1.17. Recent corporate actions include a 1:10 stock split and a $2.30 dividend, while cash flow remains positive at $101.78M in 2025. Analyst sentiment is optimistic, with a $246.93 consensus price target implying significant upside.
The outlook for KLAC is positive, driven by AI-driven semiconductor demand and robust profitability, but risks include high valuation multiples and market volatility. Investment opportunities center on growth in advanced packaging, with Wall Street largely bullish; however, investors should monitor competitive pressures and economic cycles that could impact the chip equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
